CEO’s Message

As CEO of Anavex Life Sciences Corp. (OTCBB: AVXL), I am pleased that you are taking the time to learn more about our company, its rich drug development program and its proprietary drug discovery platform.

ANAVEX has a robust pipeline of drugs in development targeting diseases of the Central Nervous System (CNS), such as Alzheimer’s disease, epilepsy and depression, as well as cancers, including those of the melanoma, prostate and pancreas. The ANAVEX drug candidates have a new, unique mechanism of action targeting the sigma receptors and the intra-cellular, mitochondrial system. This offers not only a proven symptomatic treatment mechanism of cognitive disorders but, more importantly, the potential for a disease-modifying approach of Alzheimer’s disease. This is particularly acute at a time of serial disappointments with the Amyloid plaque removal hypothesis.

In oncology, the new mechanism of action of Anavex sigma ligands offers a possible complimentary effect with existing chemotherapy because it should not share the similar side-effects and resistance. Indeed, these preliminary results will have to be tested in human clinical trials and Anavex is following the rigorous regulatory pathway to reach that goal.

Our SIGMACEPTOR™ drug discovery platform was critical to the current wealth of our portfolio. It continues to generate new drug candidates for other indications with unique modes of action. Anavex is open to discussions with academic and industrial partners to bring these discoveries further, especially outside of the core CNS and Oncology segments.

We have successfully completed most preclinical studies on ANAVEX 2-73, our lead candidate to treat Alzheimer’s disease and the IND file is in final preparation to start clinical trials early 2010. As a result of our proprietary platform, two additional drug candidates are currently in the late preclinical stage: ANAVEX 1-41 (Alzheimer’s disease and depression), ANAVEX 19-144 (epilepsy), and ANAVEX 7-1037 (Cancer). Results from these preclinical tests have very supportive of further testing in humans because of their superb in vivo efficacy and toxicity profiles. We expect to file Investigational New Drug (IND) (or IMPD) applications with regulatory authorities for these lead candidates end of 2009.

Collaborations are also extremely important to ANAVEX. We are proud to have strong partnerships with renowned European research and academic institutions such as Montpellier University, Louis Pasteur University and the Université nice SOPHIA ANTIPOLIS. These partnerships make it possible for ANAVEX to limit its R&D costs while maintaining firm control of its research efforts and intellectual property. This year we also plan to expand our collaborations beyond Europe to include major American research and academic institutions.

ANAVEX is led by a solid management team and Board of Directors with extensive experience in the pharmaceutical sector, the securities industry, business modeling and analysis, and public company administration. We are confident that our team will build on the momentum it has created and continue to grow and develop the company as we work to combat the world’s most devastating diseases.

With that, I invite you to conduct further research into Anavex Life Sciences Corp. and to contact us if you have any questions. If you are already a shareholder, we thank you for your loyalty and support. It is our hope that you will continue to participate in the ongoing success of Anavex Life Sciences Corp.

Sincerely,

Hervé de Kergrohen, MD, MBA

CEO